



THE
BLADDER CANCER
COMPANY

Photocure ASA: Exercise of employee share options

Oslo, Norway, 31 August 2021: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 30 August 2021 regarding exercise of share options.

The price for option shares sold by the primary insider, Geoffrey Coy, VP & General Manager US Operations, has been determined at a price of NOK 113.6148 per share.

The primary insider having exercised options has used the net proceeds from the sale of option shares to purchase 7,126 shares in Photocure at a price per share of NOK 113.6148 as follows:

The shares are purchased at the stated price from Photocure's holding of own shares. Following the transaction Photocure will hold 21,010 own shares.

Primary insider notification pursuant to the market abuse regulation article 19 is attached.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading Act.